Bone Biologics Extends Shelf Life Of rhNELL‑1 To 24 Months, Meeting Forecasts

Benzinga · 2d ago

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts.

The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as the Company advances rhNELL-1 through development.